Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Short overview on the current treatment of chronic myeloid leukemia in chronic phase

Short overview on the current treatment of chronic myeloid leukemia in chronic phase This short review on current treatment options in chronic myeloid leukemia (CML) in the chronic phase summarizes the latest version of the ELN treatment recommendations dating from 2013 and indicates treatment situations not yet reflected in these recommendations. Daily practice in CML management is complicated by the recently observed treatment-emergent vascular and pulmonary adverse events in second- or later-generation tyrosine kinase inhibitors (TKIs), the lack of guidance with respect to the best TKI for initial treatment, as well as the optimal TKI sequence because no prospective randomized comparative data for second- and third-generation TKIs are available. Physicians have to balance the efficacy issues and safety aspects of the respective TKI and consider patient-specific factors such as comorbidities. Patients with any cardiovascular or pulmonary disease or treatment-requiring cardiovascular risk factor should receive nilotinib or ponatinib only if risk factors and comorbidities are treated accordingly and are further monitored. If these comorbidities are insufficiently controlled, other TKIs might be preferred. Dasatinib treatment should be critically evaluated in patients with pulmonary disease and other TKIs might be preferred in this setting. For as long as CML treatment is considered to be maintained lifelong, and no survival benefit for later-generation TKIs has been demonstrated, safety issues dominate the choice of treatment options. The concept of discontinuing TKI treatment after achieving a deep molecular response might in future change these considerations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Short overview on the current treatment of chronic myeloid leukemia in chronic phase

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/short-overview-on-the-current-treatment-of-chronic-myeloid-leukemia-in-WZqHXxViGy
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0299-8
Publisher site
See Article on Publisher Site

Abstract

This short review on current treatment options in chronic myeloid leukemia (CML) in the chronic phase summarizes the latest version of the ELN treatment recommendations dating from 2013 and indicates treatment situations not yet reflected in these recommendations. Daily practice in CML management is complicated by the recently observed treatment-emergent vascular and pulmonary adverse events in second- or later-generation tyrosine kinase inhibitors (TKIs), the lack of guidance with respect to the best TKI for initial treatment, as well as the optimal TKI sequence because no prospective randomized comparative data for second- and third-generation TKIs are available. Physicians have to balance the efficacy issues and safety aspects of the respective TKI and consider patient-specific factors such as comorbidities. Patients with any cardiovascular or pulmonary disease or treatment-requiring cardiovascular risk factor should receive nilotinib or ponatinib only if risk factors and comorbidities are treated accordingly and are further monitored. If these comorbidities are insufficiently controlled, other TKIs might be preferred. Dasatinib treatment should be critically evaluated in patients with pulmonary disease and other TKIs might be preferred in this setting. For as long as CML treatment is considered to be maintained lifelong, and no survival benefit for later-generation TKIs has been demonstrated, safety issues dominate the choice of treatment options. The concept of discontinuing TKI treatment after achieving a deep molecular response might in future change these considerations.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Dec 14, 2016

References

  • A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
    Cortes, JE; Kim, DW; Pinilla-Ibarz, J; Coutre, P; Paquette, R; Chuah, C
  • Chronic myeloid leukemia: First-line drug of choice
    Jabbour, E
  • A review of the European LeukemiaNet recommendations for the management of CML
    Baccarani, M; Castagnetti, F; Gugliotta, G; Rosti, G
  • Is there a best TKI for chronic phase CML?
    Larson, RA
  • Comparative effectiveness of newer Tyrosine Kinase inhibitors versus Imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: A systematic review and meta-analysis of eight randomized trials
    Yun, S; Vincelette, ND; Segar, JM; Dong, Y; Shen, Y; Kim, DW
  • Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5‑year update of the randomized ENESTnd trial
    Hochhaus, A; Saglio, G; Hughes, TP; Larson, RA; Kim, DW; Issaragrisil, S
  • Final 5‑year study results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
    Cortes, JE; Saglio, G; Kantarjian, HM; Baccarani, M; Mayer, J; Boque, C
  • Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
    Hanfstein, B; Muller, MC; Hehlmann, R; Erben, P; Lauseker, M; Fabarius, A
  • Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
    Marin, D; Hedgley, C; Clark, RE; Apperley, J; Foroni, L; Milojkovic, D
  • Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
    Valent, P; Hadzijusufovic, E; Schernthaner, GH; Wolf, D; Rea, D; Coutre, P
  • Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
    Giles, FJ; Mauro, MJ; Hong, F; Ortmann, CE; McNeill, C; Woodman, RC
  • European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
    Steegmann, JL; Baccarani, M; Breccia, M; Casado, LF; Garcia-Gutierrez, V; Hochhaus, A
  • Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    Marin, D; Bazeos, A; Mahon, FX; Eliasson, L; Milojkovic, D; Bua, M
  • Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia
    Jabbour, EJ; Kantarjian, H; Eliasson, L; Cornelison, AM; Marin, D
  • Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
    Noens, L; Lierde, MA; Bock, R; Verhoef, G; Zachee, P; Berneman, Z
  • Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
    Noens, L; Hensen, M; Kucmin-Bemelmans, I; Lofgren, C; Gilloteau, I; Vrijens, B
  • Present and future of molecular monitoring in chronic myeloid leukaemia
    Soverini, S; Benedittis, C; Mancini, M; Martinelli, G
  • Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients
    Hochhaus, A; Ernst, T; Eigendorff, E; Rosee, P
  • Chronic myeloid leukemia: Second-line drugs of choice
    Gambacorti-Passerini, C; Aroldi, A; Cordani, N; Piazza, R
  • Second-generation Tyrosine Kinase Inhibitors (TKI) as salvage therapy for resistant or intolerant patients to prior TKIs
    Breccia, M; Alimena, G
  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    Kantarjian, HM; Giles, F; Gattermann, N; Bhalla, K; Alimena, G; Palandri, F
  • The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use
    Hanaizi, Z; Unkrig, C; Enzmann, H; Camarero, J; Sancho-Lopez, A; Salmonson, T
  • Long-term follow-up of Ponatinib efficacy and safety in the phase 2 PACE trial
    Cortes, JE; Kim, D-W; Pinilla-Ibarz, J; Coutre, P; Paquette, R; Chuah, C
  • Bosutinib as third-line therapy in patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) following failure with Imatinib plus Dasatinib and/or Nilotinib: 48-month update of a phase 1/2 study
    Gambacorti-Passerini, C; Khoury, HJ; Kantarjian, HM; Lipton, JH; Kim, D-W; Schafhausen, P
  • Dose-optimized Nilotinib (NIL) in patients (Pts) with newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): final results from ENESTxtnd Study
    Hughes, TP; Salvino, MA; Chuan, OT; Elhaddad, A; Abdulkadyrov, K; Shortt, J
  • ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single-agent activity in a phase I study of patients with CML with failure of prior TKI therapy
    Ottmann, OG; Alimena, G; DeAngelo, DJ; Goh, Y-T; Heinrich, MC; Hochhaus, A
  • Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) first line: Preliminary results of a phase II trial, from the French Intergroup of CML (Fi-LMC)
    Roy, L; Chomel, J-C; Guilhot, J; Guerci-Bresler, A; Escoffre-Barbe, M; Giraudier, S
  • Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
    Hehlmann, R; Muller, MC; Lauseker, M; Hanfstein, B; Fabarius, A; Schreiber, A
  • Personalized daily doses of Imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with chronic Myeloid leukemia. Final results of the randomized OPTIM Imatinib study
    Rousselot, P; Johnson-Ansah, H; Huguet, F; Legros, L; Escoffre-Barbe, M; Gardembas, M
  • Discontinuation of tyrosine kinase therapy in CML
    Mahon, FX